LARIMAR THERAPEUTICS

Larimar Therapeutics Reports Fourth Quarter and Full Year 2021 Operating and Financial Results

25 مارس 2022 07:00:00 بحسب Nasdaq GlobeNewswire

Larimar Therapeutics Provides Update on CTI-1601 Clinical Program

14 فبراير 2022 16:01:00 بحسب Nasdaq GlobeNewswire

Larimar Therapeutics to Participate in the Piper Sandler 33rd Annual Healthcare Conference

22 نوفمبر 2021 07:00:01 بحسب Nasdaq GlobeNewswire

Larimar Therapeutics to Participate in the Guggenheim Virtual Neuro/Immunology Conference

15 نوفمبر 2021 07:00:03 بحسب Nasdaq GlobeNewswire

Larimar Therapeutics Reports Third Quarter 2021 Operating and Financial Results

12 نوفمبر 2021 07:00:02 بحسب Nasdaq GlobeNewswire

Larimar Therapeutics to Participate in SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases & Genetic Medicines Event

16 سبتمبر 2021 08:00:02 بحسب Nasdaq GlobeNewswire

Larimar Therapeutics to Present at the Morgan Stanley 19th Annual Global Healthcare Conference

02 سبتمبر 2021 16:01:00 بحسب Nasdaq GlobeNewswire

Larimar Therapeutics Announces Upcoming Oral Presentation at the World Orphan Drug Congress

19 أغسطس 2021 07:00:00 بحسب Nasdaq GlobeNewswire

Larimar Therapeutics Reports Second Quarter 2021 Operating and Financial Results

12 أغسطس 2021 07:00:01 بحسب Nasdaq GlobeNewswire

Larimar Therapeutics to Present at the William Blair Biotech Focus Conference 2021

08 يوليو 2021 16:01:00 بحسب Nasdaq GlobeNewswire

Larimar Therapeutics to Present at the JMP Securities Life Sciences Conference

11 يونيو 2021 07:00:00 بحسب Nasdaq GlobeNewswire

Larimar Therapeutics Reports FDA Clinical Hold on CTI-1601 and Termination of Recently Announced Private Placement Financing

25 مايو 2021 17:41:45 بحسب Nasdaq GlobeNewswire

Larimar Therapeutics Announces $95 Million Private Placement Financing

21 مايو 2021 09:18:23 بحسب Nasdaq GlobeNewswire

Larimar Therapeutics Receives European Medicines Agency Priority Medicines (PRIME) Designation for CTI-1601 in Friedreich’s Ataxia

20 مايو 2021 16:31:11 بحسب Nasdaq GlobeNewswire

Larimar Therapeutics Reports Positive Topline Phase 1 Clinical Trial Data Showing Dose-Dependent Increases in Frataxin Levels in Patients with Friedreich’s Ataxia

11 مايو 2021 07:00:01 بحسب Nasdaq GlobeNewswire

Larimar Therapeutics Reports First Quarter 2021 Operating and Financial Results

10 مايو 2021 16:05:01 بحسب Nasdaq GlobeNewswire

Larimar Therapeutics Reports Fourth Quarter and Full Year 2020 Operating and Financial Results

04 مارس 2021 07:00:01 بحسب Nasdaq GlobeNewswire

Larimar Therapeutics to Present at the SVB Leerink 10th Annual Global Healthcare Conference

18 فبراير 2021 16:01:00 بحسب Nasdaq GlobeNewswire